Finally, the tumor growth suppressive effects of DHE also extended to a MOLM-14 cell xenograft model of MLL-rearranged AML and were DHE dose-responsive at clinically-relevant doses of DHE (Supplemental Fig. 12). This evidence concerns the gene KMT2A and acute myeloid leukemia.